Sakagami Masahiro, Kinoshita Wataru, Sakon Kiyoyuki, Sato Jun-ichi, Makino Yuji
DDS Research Laboratories, Teijin Ltd., Asahigaoka, Hino, Tokyo 191-8512, Japan.
J Control Release. 2002 Apr 23;80(1-3):207-18. doi: 10.1016/s0168-3659(02)00034-2.
The feasibility of prolonging drug action and/or reducing drug dosage using mucoadhesive beclomethasone dipropionate (BDP) microspheres for powder inhalation was investigated. BDP was spray-dried from ethanol solution or aqueous suspension systems dissolving a mucoadhesive polymer, hydroxypropylcellulose (HPC); this resulted in amorphous and crystalline BDP incorporation in the HPC microspheres (aBDP/HPC and cBDP/HPC; BDP-HPC ratio=1:4), respectively. These microspheres were administered as powder aerosols to healthy or antigen-induced, asthmatic guinea pigs, and BDP's retention in the lung (pharmacokinetics) and inhibitory duration with respect to eosinophil infiltration into the airways (pharmacodynamics) were compared to those for pure crystalline BDP (cBDP; 'control'). Both BDP/HPC microspheres were prepared within a respirable-size range of 2.5-2.9 microm. BDP's aqueous solubility was increased 25 times for aBDP/HPC, compared to crystalline counterpart. Pharmacokinetic profiles for three powders were dissolution-modulated. aBDP/HPC showed rapid BDP absorption from the lung (> or = 95% absorption for 180 min) with a greater metabolite (B17MP) formation, compared to cBDP, primarily due to the increased dissolution of amorphous BDP. In contrast, 86.0% of BDP remained at 180 min following cBDP/HPC administration, demonstrating the prolonged BDP's retention in the lung by virtue of poor dissolution (and/or release) and retarded mucociliary clearance. As a result, while cBDP (1.37 mg/kg) significantly inhibited eosinophil infiltration into the lungs of antigen-sensitized and -challenged guinea pigs for only 1-6 h, cBDP/HPC, despite a much lower drug dosage (0.25 mg/kg), was capable of maintaining such inhibitory effects for 24 h following administration. It appeared therefore that the prolonged lung retention of BDP by the use of the HPC microspheres (cBDP/HPC) was attributed to prolonging its pharmacological duration without requiring increased drug dosage.
研究了使用用于粉末吸入的粘膜粘附性二丙酸倍氯米松(BDP)微球延长药物作用和/或降低药物剂量的可行性。BDP从溶解有粘膜粘附聚合物羟丙基纤维素(HPC)的乙醇溶液或水性悬浮体系中喷雾干燥;这分别导致无定形和结晶形BDP掺入HPC微球中(aBDP/HPC和cBDP/HPC;BDP-HPC比例=1:4)。将这些微球作为粉末气雾剂给予健康的或抗原诱导的哮喘豚鼠,并将BDP在肺中的滞留情况(药代动力学)以及对嗜酸性粒细胞浸润气道的抑制持续时间(药效动力学)与纯结晶BDP(cBDP;“对照”)的情况进行比较。两种BDP/HPC微球均在2.5-2.9微米的可吸入尺寸范围内制备。与结晶形式的对应物相比,aBDP/HPC的BDP水溶性增加了25倍。三种粉末的药代动力学曲线受溶出调节。与cBDP相比,aBDP/HPC显示出BDP从肺中快速吸收(180分钟内吸收≥95%),且代谢物(B17MP)形成更多,这主要是由于无定形BDP溶出增加。相反,给予cBDP/HPC后180分钟时86.0%的BDP仍留存,这表明由于溶出不良(和/或释放)以及粘液纤毛清除延迟,BDP在肺中的滞留时间延长。结果,虽然cBDP(1.37mg/kg)仅在1-6小时内显著抑制抗原致敏和激发的豚鼠肺中嗜酸性粒细胞浸润,但cBDP/HPC尽管药物剂量低得多(0.25mg/kg),给药后仍能将这种抑制作用维持24小时。因此,似乎通过使用HPC微球(cBDP/HPC)延长BDP在肺中的滞留时间可归因于在不增加药物剂量的情况下延长其药理作用持续时间。